Author

Ferdinando D'Amico

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

Ferdinando D'Amico  et al.

International consensus on methodological issues in standardization of fecal calprotectin measurement in IBD
International consensus on methodological issues in standardization of fecal calprotectin measurement in IBD

Ferdinando D'Amico  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

Ferdinando D'Amico  et al.

Item 1 - 3 / 3
1